Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGattaca Regulatory News (GATC)

Share Price Information for Gattaca (GATC)

Share Price is delayed by 15 minutes
Get Live Data
147.50    -1.50 (-1.01%)
Bid:
145.00
Ask:
150.00
Spread: 5.00 (3.448%)
Market Cap: £45.56m
GATC Live PriceLast checked at - London Stock Exchange

Intraday Gattaca Share Chart

Trading Update

15 Feb 2024 07:00

RNS Number : 1917D
Gattaca PLC
15 February 2024
Β 

15 February 2024

Β 

Gattaca plc

Β 

("Gattaca" or the "Group")

Β 

Trading Update

Robust performance in line with market expectations

Β 

Gattaca plc, the specialist staffing solutions business, today provides the following trading update for the six months ended 31 January 2024 ("H1 24").

Β 

Β·

Group Net Fee Income1 ("NFI") expected to be Β£18.9m (H1 232 Β£22.5m), a decrease of 16% year-on-year ("YoY")

Β·

NFI shows anticipated shift towards Contract 76% / Permanent 24% (H1 232: 68% / 32%), reflecting increased focus on contract market and maintaining contractor volumes which ended the period flat with the prior year

Β·

Permanent NFI down 38% YoY as a result of market weakness, with placements continuing to show weakness since the turn of the year, and the exit of a large permanent Recruitment Process Outsourcing ("RPO") client in prior year as referenced at year end

Β·

Significant progress in business development, with two large client extensions and two more Managed Service Provider wins

Β·

Defence continues to be the Group's strongest performing sector with 9% YoY growth excluding the RPO account exit as above

Β·

Marginal reduction in sales headcount during H1 24 to 312 from 315 at the year-end, focused UK headcount investment in specific sectors showing growth opportunities, these being Energy, Defence and Gattaca Projects

Β·

The Group expects to report statutory net cash at 31 January 2024 of Β£22.1m (31 July 2023: net cash of Β£21.6m)

Β 

Β 

Notice of Interim Results

The Group will announce its results for the six months to 31 January 2024 on Tuesday 16 April 2024.

Β 

Β 

Matthew Wragg, Chief Executive Officer said:

"Despite the tough market conditions, I am pleased to report the Group is trading in line with current market expectations. I am also pleased to see our strategy to invest in business development is starting to bear fruit, with two large client extensions and two more Managed Service Provider (MSP) wins for the Group in H1 and a growing pipeline. We continue to see high engagement, staff attrition below long-term targets and productivity levels beginning to improve. In H1 we have continued to focus the business more on specific markets and geographies. We have reduced our workforce in North America.

Β 

However, the economic conditions have led to a challenging market in H1 and we have not been immune to this. Permanant fee income is down 38% due to much lower than anticipated volumes at the back end of 2023 and compounded by reduced NFI from the exiting of a major programme last year. We anticipate that Permanant fees will pick up gradually as we go through 2024. Contract income has remained stable, and we are starting to see growth from our investment and focus into this area.

Β 

Recognising that trading conditions are expected to remain challenging, we plan to keep tight control on operating costs including headcount during H2, whilst we are mindful to ensure we are well placed to build market share in our chosen sectors as the economy recovers.

Β 

I would like to add my personal thanks to everyone in and from the business, our special community, customers and partners for their support in what has been an extremely tough week for the Group following the sudden passing of our very good friend and Chief Sales Officer Grahame Carter. The way everyone has united is testament to the strength we have as a team. Our love and condolences go to his family, friends and everyone who had the pleasure to know him."

Β 

Β 

1. NFI is calculated as revenue less contractor payroll costs

2. H1 23 results have been restated for the correction of a FY22 revenue cut-off error, and the FY23 reassessment of the Group's accounting policy over how accrued revenue and accrued cost balances have been calculated at the period end. The aggregated impact of these items on H1 23 reported NFI is Β£0.2m reduction. Further details on this error and policy change were provided in the Group's FY23 Annual Report & Accounts.

Β 

Β 

Β 

For further information please contact:

Β 

Gattaca plc

+44 (0) 1489 898989

Matthew Wragg, Chief Executive OfficerΒ 

Oliver Whittaker, Chief Financial Officer

Liberum Capital Limited (Nomad and Broker)

+44 (0) 20 3100 2000

Lauren Kettle

Richard Lindley

IFC Advisory (Financial PR and IR)

+44 (0) 203 934 6630

Tim Metcalfe

Graham Herring

Florence Chandler

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTBIGDDUXBDGSS
Date   Source Headline
14th May 20267:00 amRNSTrading Update
1st Apr 20267:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
24th Mar 20267:00 amRNSInterim Results
11th Mar 20267:00 amRNSNotice of Results and Investor Presentations
11th Mar 20267:00 amRNSNotice of Results and Investor Presentations
11th Feb 20267:00 amRNSTrading Update
31st Dec 20257:00 amRNSDirector/PDMR dealing
31st Dec 20257:00 amRNSDirector/PDMR dealing
19th Dec 20253:29 pmRNSGrant of Options and Director/PDMR dealing
19th Dec 20253:29 pmRNSGrant of Options and Director/PDMR dealing
16th Dec 202512:19 pmRNSExercise of Options and Director/PDMR Shareholding
11th Dec 20259:05 amRNSResults of Annual General Meeting
10th Nov 20257:00 amRNSAvailability of Report & Accounts and AGM Notice
23rd Oct 20257:00 amRNSFinal results for the year ended 31 July 2025
15th Oct 20257:00 amRNS-RInvestor Presentation via Investor Meet Company
13th Oct 20252:59 pmRNSBlock Listing Six Monthly return
8th Oct 20257:00 amRNSNotice of Results
5th Aug 20257:00 amRNSTrading update and Acquisition
22nd Jul 20257:00 amRNSEBT Share Purchase Programme
21st Jul 20256:22 pmRNSExercise of Options and Director/PDMR Shareholding
2nd Apr 20252:21 pmRNSCORRECTION – Interim Results
2nd Apr 20257:00 amRNSInterim Results
1st Apr 20257:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
13th Feb 20257:00 amRNSTrading Update
27th Jan 20254:51 pmRNSFurther re EBT Share Purchase Programme
11th Dec 20243:59 pmRNSDirector/PDMR Shareholding
11th Dec 20242:25 pmRNSResult of AGM
11th Nov 20242:29 pmRNSAvailability of Report & Accounts and AGM Notice
30th Oct 20247:00 amRNSEBT Share Purchase Programme
24th Oct 20247:00 amRNSFinal results for the year ended 31 July 2024
1st Oct 20247:00 amRNSBlock listing Six Monthly Return
15th Aug 20247:00 amRNSTrading Update for the year ended 31 July 2024
16th Jul 202410:36 amRNSDirector/PDMR Share Purchase
11th Jul 202411:13 amRNSExercise of Options
1st Jul 20247:00 amRNSNominated Adviser and Broker
16th Apr 20247:00 amRNSInterim Results
2nd Apr 20247:00 amRNSBlock listing six monthly return
15th Feb 20247:00 amRNSTrading Update
25th Jan 20247:00 amRNSExercise of Options
6th Dec 20235:07 pmRNSDirector/PDMR Shareholding
6th Dec 20234:51 pmRNSResults of Annual General Meeting
28th Nov 20237:00 amRNSTransaction in Own Shares
27th Nov 20237:00 amRNSTransaction in Own Shares
24th Nov 20237:00 amRNSTransaction in Own Shares
22nd Nov 20237:00 amRNSTransaction in Own Shares
21st Nov 20237:00 amRNSTransaction in Own Shares
20th Nov 20237:00 amRNSTransaction in Own Shares
17th Nov 20237:00 amRNSTransaction in Own Shares
15th Nov 20237:00 amRNSTransaction in Own Shares
14th Nov 20237:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.